Shareholder Alert: Ademi LLP investigates whether Reneo Pharmaceuticals, Inc. has obtained a Fair Price in its Transaction with OnKure

MILWAUKEE, May 13, 2024 /PRNewswire/ -- Ademi LLP is investigating Reneo (Nasdaq: RPHM) for possible breaches of fiduciary duty and other violations of law in its going private transaction with OnKure.

Click here to learn how to join the https://www.ademilaw.com/case/reneo-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, pre-merger Reneo stockholders are expected to own approximately 31% of the combined company, and pre-merger OnKure stockholders are expected to own approximately 69% of the combined company. The transaction agreement unreasonably limits competing transactions for Reneo by imposing a significant penalty if Reneo accepts a competing bid. Reneo insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Reneo's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Reneo common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/reneo-pharmaceuticals-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED